These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 9220319)

  • 41. Interleukin-2-induced renal dysfunction in cancer patients is reversed by low-dose dopamine infusion.
    Memoli B; De Nicola L; Libetta C; Scialò A; Pacchiano G; Romano P; Palmieri G; Morabito A; Lauria R; Conte G
    Am J Kidney Dis; 1995 Jul; 26(1):27-33. PubMed ID: 7611264
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Phase I study of recombinant interleukin-21 in patients with metastatic melanoma and renal cell carcinoma.
    Thompson JA; Curti BD; Redman BG; Bhatia S; Weber JS; Agarwala SS; Sievers EL; Hughes SD; DeVries TA; Hausman DF
    J Clin Oncol; 2008 Apr; 26(12):2034-9. PubMed ID: 18347008
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Sequential interleukin-2 and alpha interferon for renal cell carcinoma and melanoma.
    Thomas H; Barton C; Saini A; Dalgleish A; Waxman J
    Eur J Cancer; 1992; 28A(6-7):1047-9. PubMed ID: 1627371
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Thyroid dysfunction in 281 patients with metastatic melanoma or renal carcinoma treated with interleukin-2 alone.
    Krouse RS; Royal RE; Heywood G; Weintraub BD; White DE; Steinberg SM; Rosenberg SA; Schwartzentruber DJ
    J Immunother Emphasis Tumor Immunol; 1995 Nov; 18(4):272-8. PubMed ID: 8680655
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Combination therapy with interferon alfa-2a and interleukin-2 for the treatment of metastatic cancer.
    Marincola FM; White DE; Wise AP; Rosenberg SA
    J Clin Oncol; 1995 May; 13(5):1110-22. PubMed ID: 7738617
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Results of two sequential phase II studies of interleukin-2 (IL2) in metastatic renal cell carcinoma and melanoma: high-dose continuous intravenous IL2 infusion and subcutaneous IL2 administration in combination with alpha interferon.
    Hidalgo OF; Aramendía JM; Alonso G; Foncillas JG; Brugarolas A
    Rev Med Univ Navarra; 1996; 40(3):6-12. PubMed ID: 9499820
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A combination of subcutaneous recombinant interleukin-2 and recombinant interferon-alpha in the treatment of advanced renal cell carcinoma or melanoma.
    Vuoristo M; Jantunen I; Pyrhönen S; Muhonen T; Kellokumpu-Lehtinen P
    Eur J Cancer; 1994; 30A(4):530-2. PubMed ID: 8018415
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Daily alternating administration of high-dose alpha-2b-interferon and interleukin-2 bolus infusion in metastatic renal cell cancer. A phase II study.
    Bergmann L; Fenchel K; Weidmann E; Enzinger HM; Jahn B; Jonas D; Mitrou PS
    Cancer; 1993 Sep; 72(5):1733-42. PubMed ID: 8348502
    [TBL] [Abstract][Full Text] [Related]  

  • 49. High-dose continuous intravenous infusion of interleukin-2 therapy for metastatic renal cell carcinoma: the University of Chicago experience.
    Shulman KL; Stadler WM; Vogelzang NJ
    Urology; 1996 Feb; 47(2):194-7. PubMed ID: 8607232
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Renal toxicity of interleukin-2 administration in patients with metastatic renal cell cancer: effect of pre-therapy nephrectomy.
    Belldegrun A; Webb DE; Austin HA; Steinberg SM; Linehan WM; Rosenberg SA
    J Urol; 1989 Mar; 141(3):499-503. PubMed ID: 2783983
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Activity of continuous infusion plus pulse interleukin-2 with famotidine in patients with metastatic kidney cancer or melanoma previously treated with interleukin-2.
    Quan WD; Walker PR; Quan FM; Ramirez M; Elsamaloty HM; Ghai V; Vinogradov M; Liles DK
    Cancer Biother Radiopharm; 2006 Oct; 21(5):437-42. PubMed ID: 17105418
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The role of possible risk factors for acute and late renal dysfunction after high-dose interleukin-2, interferon alpha and lymphokine-activated killer cells.
    Kruit WH; Schmitz PI; Stoter G
    Cancer Immunol Immunother; 1999 Sep; 48(6):331-5. PubMed ID: 10473808
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Randomized phase II trial of high-dose interleukin-2 either alone or in combination with interferon alfa-2b in advanced renal cell carcinoma.
    Atkins MB; Sparano J; Fisher RI; Weiss GR; Margolin KA; Fink KI; Rubinstein L; Louie A; Mier JW; Gucalp R
    J Clin Oncol; 1993 Apr; 11(4):661-70. PubMed ID: 8478661
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Adjuvant adoptive immunotherapy with tumour-infiltrating lymphocytes and modulated doses of interleukin-2 in 22 patients with melanoma, colorectal and renal cancer, after radical metastasectomy, and in 12 advanced patients.
    Ridolfi R; Flamini E; Riccobon A; De Paola F; Maltoni R; Gardini A; Ridolfi L; Medri L; Poletti G; Amadori D
    Cancer Immunol Immunother; 1998 Jun; 46(4):185-93. PubMed ID: 9671141
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Phase III randomized trial of interleukin-2 with or without lymphokine-activated killer cells in the treatment of patients with advanced renal cell carcinoma.
    Law TM; Motzer RJ; Mazumdar M; Sell KW; Walther PJ; O'Connell M; Khan A; Vlamis V; Vogelzang NJ; Bajorin DF
    Cancer; 1995 Sep; 76(5):824-32. PubMed ID: 8625186
    [TBL] [Abstract][Full Text] [Related]  

  • 56. A prospective randomized trial evaluating colloid versus crystalloid resuscitation in the treatment of the vascular leak syndrome associated with interleukin-2 therapy.
    Pockaj BA; Yang JC; Lotze MT; Lange JR; Spencer WF; Steinberg SM; Topalian SL; Schwartzentruber DJ; White DE; Rosenberg SA
    J Immunother Emphasis Tumor Immunol; 1994 Jan; 15(1):22-8. PubMed ID: 8110727
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy.
    Fyfe G; Fisher RI; Rosenberg SA; Sznol M; Parkinson DR; Louie AC
    J Clin Oncol; 1995 Mar; 13(3):688-96. PubMed ID: 7884429
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The effect of 'renal-dose' dopamine on renal tubular function following cardiac surgery: assessed by measuring retinol binding protein (RBP).
    Tang AT; El-Gamel A; Keevil B; Yonan N; Deiraniya AK
    Eur J Cardiothorac Surg; 1999 May; 15(5):717-21; discussion 721-2. PubMed ID: 10386423
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Should we give prophylactic renal-dose dopamine after coronary artery bypass surgery?
    Gatot I; Abramov D; Tsodikov V; Yeshayahu M; Orman S; Gavriel A; Chorni I; Tuvbin D; Tager S; Apelbom A
    J Card Surg; 2004; 19(2):128-33. PubMed ID: 15016048
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin 2.
    Rosenberg SA; Yannelli JR; Yang JC; Topalian SL; Schwartzentruber DJ; Weber JS; Parkinson DR; Seipp CA; Einhorn JH; White DE
    J Natl Cancer Inst; 1994 Aug; 86(15):1159-66. PubMed ID: 8028037
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.